Cboe BZX · PTNTHealthcarePharmaceuticals

Corgi IP Licensing & Royalties ETF financials

$24.11−1.84%
Close Sep 28, 2026 · split-adjusted

Revenue

Net income

Income statement & cash flow

QuarterQ4 '26
Jun 30
Revenue$300.8K
Gross profit$300.8K
Gross margin100.0%
Operating income-$4.4M
Net income-$4.4M
Net margin−1449.1%
Diluted EPS$-1.16
EBITDA-$4.4M
Operating cash flow-$2.7M
Free cash flow-$2.7M
Diluted shares3.8M

Balance sheet

Period endJun 30
Cash & equivalents$7.5M
Short-term investments$0.00
Total debt$0.00
Total assets$8.5M
Total liabilities$1.8M
Shareholders' equity$6.7M

From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology